Masimo to Report Third Quarter 2022 Financial Results after Market Close on Tuesday, November 8
Masimo (NASDAQ: MASI) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call hosted by CEO Joe Kiani and CFO Micah Young will occur at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. This event is crucial for investors as Masimo's innovative medical technologies aim to improve patient outcomes and reduce care costs. Interested participants can register for the call to receive necessary details. More information about Masimo and its products is available on its website.
- Strong focus on innovative monitoring technologies to enhance healthcare.
- The company's products are used on over 100 million patients globally.
- Nine of the top ten hospitals utilize Masimo SET technology.
- None.
Conference call and webcast to begin at
To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participants via email.
Conference Call Registration Link (Please register to obtain the dial-in number):
https://conferencingportals.com/event/nUSpRIEm
A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.
About Masimo
Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005430/en/
Investor Contact:
(949) 297-7077
ekammerman@masimo.com
Media Contact:
(949) 297-3376
elamb@masimo.com
Source: Masimo
FAQ
When will Masimo release its third quarter 2022 financial results?
What time is the Masimo conference call for Q3 2022 results?
Who will host the Masimo conference call?
How can I attend the Masimo financial results conference call?